Pioneering novel GPCR-directed therapeutics for metabolic & endocrine diseases

Confo is creating new medicines with its unique approach

Our pipeline Our technology

The field of GPCR-modulating therapeutics is rapidly evolving

Confo Therapeutics is a clinical-stage company committed to identifying & accelerating novel medicines for metabolic & endocrine diseases.

With our proprietary technology, we develop both small molecules & antibody-based therapies creating new treatment opportunities for patients.

Learn more about us

How we do this

Creating novel GPCR-directed therapeutics

Our proprietary, cutting-edge technology targets & modulates GPCRs to discover small molecule & antibody-based therapeutics.

Our approach can target class A & B GPCRs in new ways to discover agonists, antagonists, inverse agonists and allosteric modulators.

Tour our technology

Our team of innovators is advancing our pipeline, inventing new paths forward for patients. We’re also partnering with pharma companies that share our ambition to deliver novel product candidates using our proprietary approach.

Advancing our pipeline

Our programs focus on small molecule and antibody-based therapeutics

Peripheral Pain

Target: AT2R

Approach: Antagonist

Peripheral Pain

Target: AT2R

Approach: Antagonist

Phase 1

700

mil.

By 2050, over 700 million people worldwide are estimated to suffer from neuropathic pain, highlighting the urgent need for innovative treatments and effective management strategies to improve quality of life.

7-10

%

Neuropathic pain affects an estimated 7-10% of the global population, highlighting its widespread impact and the need for effective treatment solutions.

Phase 1

700

mil.

7-10

%

Neuropathic pain affects an estimated 7-10% of the global population, highlighting its widespread impact and the need for effective treatment solutions.

Confo Therapeutics is developing CFTX-1554, a non-opioid treatment for neuropathic pain. It targets the angiotensin II type 2 receptor (AT2R), addressing prior challenges of off-target toxicity in pain management.